# US 2012/0238727 A1 · Decorin compositions and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0238727 A1
- Document ID: US20120238727A1
- Status: Published application
- Kind: A1
- Application number: 13/419,045
- Filed: 2012-03-13
- Published: 2012-09-20
- Earliest claimed: 2011-03-14
- Assignees: Catalent Pharma Solutions, LLC
- Inventors: Gregory Thomas Bleck; Ian John Collins; Mark Joseph Frey
- Web page: https://patentgrep.com/patent/US20120238727A1

## CPC

- C07K 14/4725: {Proteoglycans, e.g. aggreccan}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C07K 2319/036: targeting to the medium outside of the cell, e.g. type III secretion
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to improved decorin compositions and methods of their production.

## Claims

### Claim 1

A fusion protein comprising a heterologous signal peptide operably linked to a sequence encoding decorin.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein said signal sequence is an alpha-lactalbumin signal sequence.

### Claim 3 (depends on 2)

The fusion protein of claim 2, wherein said alpha lactalbumin sequence is a bovine alpha-lactalbumin signal sequence.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein said sequence encoding decorin encodes a decorin core protein.

### Claim 5 (depends on 4)

The fusion protein of claim 4, wherein said decorin core protein comprises a mutation at position 4 of the mature decorin core protein.

### Claim 6 (depends on 5)

The fusion protein of claim 5, wherein said mutation is a serine to alanine mutation.

### Claim 7 (depends on 4)

The fusion protein of claim 4, wherein said decorin core protein lacks substantial modification by glycosaminoglycans molecules at position 4 of the mature decorin core protein.

### Claim 8 (depends on 1)

A vector encoding the fusion protein of claim 1.

### Claim 9 (depends on 8)

The vector of claim 8, wherein said vector comprises a nucleic acid sequence encoding an alpha-lactalbumin signal sequence operably linked to a sequence encoding a decorin core protein.

### Claim 10 (depends on 8)

A host cell comprising the vector of claim 8.

### Claim 11

A method of producing a non-gagylated decorin core protein comprising:
providing host cells expressing non-gagylated decorin core protein;
culturing said host cell so that said non-gagylated decorin core protein is produced; and
purifying said non-gagylated decorin core protein.

### Claim 12 (depends on 11)

The method of claim 11, wherein said non-gagylated decorin core protein is secreted into medium used to culture said host cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein said purifying comprises contacting said culture medium with an ion exchange medium.

### Claim 14 (depends on 12)

The method of claim 12, wherein said purifying comprises contacting said culture medium with a hydroxyapatite medium.

### Claim 15 (depends on 12)

The method of claim 12, wherein said purifying comprises contacting said culture medium with at least one ion exchange medium and at least one hydroxyapatite medium in any order.

### Claim 16 (depends on 12)

The method of claim 12, wherein said purifying comprises:
contacting said culture medium with a cation exchange medium;
washing said cation exchange medium;
eluting a first decorin-containing eluate from said cation exchange medium;
contacting said first decorin-containing eluate with a hydroxyapatite medium;
washing said hydroxyapatite medium;
eluting a second decorin-containing eluate from said hydroxyapatite medium.

### Claim 17 (depends on 16)

The method of claim 16, wherein said cation exchange medium is SP-Sepharose FF.

### Claim 18 (depends on 16)

The method of claim 16, wherein said hydroxyapatite medium is ceramic hydroxyapatite type I.

### Claim 19 (depends on 16)

The method of claim 16, further comprising further purification of said second decorin-containing eluate with an ion exchange membrane or column.

### Claim 20 (depends on 19)

The method of claim 19, wherein said ion exchange membrane is a Q ion exchange membrane.

### Claim 21 (depends on 16)

The method of claim 16, further comprising a viral inactivation step.

### Claim 22 (depends on 21)

The method of claim 21, wherein said viral inaction step comprises treatment with a surfactant.

### Claim 23 (depends on 22)

The method of claim 22, wherein said surfactant is Triton X-100.

### Claim 24 (depends on 16)

The method of claim 16, further comprising a viral filtration step.

### Claim 25 (depends on 16)

The method of claim 16, further comprising concentrating said decorin.

### Claim 26 (depends on 11)

The method of claim 11, wherein said non-gagylated decorin core protein is produced by said host cells at a rate of about greater than 1, 5, or 10 pg/cell/day.

### Claim 27

A method for purifying decorin from a decorin-containing medium comprising:
contacting said decorin-containing medium with a cation exchange medium;
washing said cation exchange medium;
eluting a first decorin-containing eluate from said cation exchange medium;
contacting said at first decorin-containing eluate with a hydroxyapatite medium;
washing said hydroxyapatite medium;
eluting a second decorin-containing eluate from said hydroxyapatite medium;
filtering said second decorin-containing eluate with an ion exchange membrane to provide a decorin-containing filtrate;
treating said filtrate to remove viruses;
concentrating decorin from said filtrate.

### Claim 28

A composition comprising a purified decorin core protein comprising a mutation at position 4 of the mature decorin core protein so that said decorin protein is substantially non-gagylated, said composition comprising less than about 100 ng residual host cell protein/mg decorin core protein in said composition and less than about 20 pg residual host cell DNA/mg decorin core protein.

### Claim 29 (depends on 28)

The composition of claim 28, said composition comprising less than about 5 ng residual host cell protein/mg decorin core protein in said composition and less than about 5 pg residual host cell DNA/mg decorin core protein.

### Claim 30 (depends on 28)

The composition of claim 28, wherein said decorin is formulated as an aqueous solution.

### Claim 31 (depends on 30)

The composition of claim 30, wherein said aqueous solution comprises a phosphate buffered solution with a pH of from about 6.5 to about 7.5.
